{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:13:36Z","timestamp":1793240016153,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82360701"],"award-info":[{"award-number":["82360701"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-025-07929-9","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T23:03:22Z","timestamp":1742943802000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Inhibitory efficacy and structural insights of Bofutrelvir against SARS-CoV-2 Mpro mutants and MERS-CoV Mpro"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7332-8217","authenticated-orcid":false,"given":"Weiwei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0614-6903","authenticated-orcid":false,"given":"Qisheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9511-4219","authenticated-orcid":false,"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"7929_CR1","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S0140-6736(03)14630-2","volume":"362","author":"N. S. Zhong","year":"2003","unstructured":"Zhong, N. S. et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People\u2019s Republic of China, in February, 2003.  Lancet 362, 1353\u20131358 (2003).","journal-title":"Lancet"},{"key":"7929_CR2","doi-asserted-by":"publisher","first-page":"152","DOI":"10.7861\/clinmedicine.4-2-152","volume":"4","author":"P. Vijayanand","year":"2004","unstructured":"Vijayanand, P., Wilkins, E. & Woodhead, M. Severe acute respiratory syndrome (SARS): a review. Clin. Med. 4, 152\u2013160 (2004).","journal-title":"Clin. Med."},{"key":"7929_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jcv.2003.09.011","volume":"29","author":"A. Berger","year":"2004","unstructured":"Berger, A., Drosten, C., Doerr, H., St\u00fcrmer, M. & Preiser, W. Severe acute respiratory syndrome (SARS)\u2014paradigm of an emerging viral infection. J. Clin. Virol. 29, 13\u201322 (2004).","journal-title":"J. Clin. Virol."},{"key":"7929_CR4","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1007\/s00705-014-1995-5","volume":"159","author":"A.S. Abdel-Moneim","year":"2014","unstructured":"Abdel-Moneim, A.S. Middle East respiratory syndrome coronavirus (MERS-CoV): evidence and speculations. Arch. Virol. 159, 1575\u20131584 (2014).","journal-title":"Arch. Virol."},{"key":"7929_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1146\/annurev-med-051215-031152","volume":"68","author":"A.R. Fehr","year":"2017","unstructured":"Fehr, A.R., Channappanavar, R. & Perlman, S. Middle east respiratory syndrome: emergence of a pathogenic human coronavirus. Annu. Rev. Med. 68, 387\u2013399 (2017).","journal-title":"Annu. Rev. Med."},{"key":"7929_CR6","doi-asserted-by":"publisher","first-page":"138996","DOI":"10.1016\/j.scitotenv.2020.138996","volume":"730","author":"T. Acter","year":"2020","unstructured":"Acter, T. et al. Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: A global health emergency. Sci. Total Environ. 730, 138996 (2020).","journal-title":"Sci. Total Environ."},{"key":"7929_CR7","doi-asserted-by":"crossref","unstructured":"Lauxmann, M. A., Santucci, N. E. & Autr\u00e1n-G\u00f3mez, A. M. The SARS-CoV-2 coronavirus and the COVID-19 outbreak. Int. Braz. J. Urol. 46, 6\u201318 (2020).","DOI":"10.1590\/s1677-5538.ibju.2020.s101"},{"key":"7929_CR8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s12063-021-00179-y","volume":"15","author":"Z. Yu","year":"2022","unstructured":"Yu, Z. et al. Disruption in global supply chain and socio-economic shocks: a lesson from COVID-19 for sustainable production and consumption. Oper. Manag. Res. 15, 233\u2013248 (2022).","journal-title":"Oper. Manag. Res."},{"key":"7929_CR9","doi-asserted-by":"crossref","unstructured":"Clemente-Su\u00e1rez, V. J. et al. The impact of the COVID-19 pandemic on social, health, and economy. Sustainability 13, 6314 (2021).","DOI":"10.3390\/su13116314"},{"key":"7929_CR10","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1001\/jama.2020.14103","volume":"324","author":"H.C. Prescott","year":"2020","unstructured":"Prescott, H.C. & Girard, T.D. Recovery from severe COVID-19: leveraging the lessons of survival from sepsis. JAMA 324, 739\u2013740 (2020).","journal-title":"JAMA"},{"key":"7929_CR11","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3390\/biochem4030014","volume":"4","author":"N.N. Magwaza","year":"2024","unstructured":"Magwaza, N.N. et al. Mechanistic insights into targeting SARS-CoV-2 papain-like protease in the evolution and management of COVID-19. BioChem 4, 268\u2013299 (2024).","journal-title":"BioChem"},{"key":"7929_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112711","volume":"206","author":"Y. Liu","year":"2020","unstructured":"Liu, Y. et al. The development of Coronavirus 3C-Like protease (3CLpro) inhibitors from 2010 to 2020. Eur. J. Med. Chem. 206, 112711 (2020).","journal-title":"Eur. J. Med. Chem."},{"key":"7929_CR13","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.drudis.2020.12.005","volume":"26","author":"R. Banerjee","year":"2021","unstructured":"Banerjee, R., Perera, L. & Tillekeratne, L. M. V. Potential SARS-CoV-2 main protease inhibitors. Drug Discov. Today 26, 804\u2013816 (2021).","journal-title":"Drug Discov. Today"},{"key":"7929_CR14","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1021\/acscombsci.0c00058","volume":"22","author":"B. Goyal","year":"2020","unstructured":"Goyal, B. & Goyal, D. Targeting the dimerization of the main protease of coronaviruses: a potential broad-spectrum therapeutic strategy. ACS Comb. Sci. 22, 297\u2013305 (2020).","journal-title":"ACS Comb. Sci."},{"key":"7929_CR15","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s11010-022-04393-5","volume":"477","author":"F. Anjum","year":"2022","unstructured":"Anjum, F. et al. Identification of intrinsically disorder regions in non-structural proteins of SARS-CoV-2: New insights into drug and vaccine resistance. Mol. Cell. Biochem. 477, 1607\u20131619 (2022).","journal-title":"Mol. Cell. Biochem."},{"key":"7929_CR16","doi-asserted-by":"publisher","first-page":"115772","DOI":"10.1016\/j.ejmech.2023.115772","volume":"260","author":"X. Li","year":"2023","unstructured":"Li, X. & Song, Y. Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review. Eur. J. Med. Chem. 260, 115772 (2023).","journal-title":"Eur. J. Med. Chem."},{"key":"7929_CR17","doi-asserted-by":"crossref","unstructured":"Kneller, D. W. et al. Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography. Nat. Commun. 11, 3202 (2020).","DOI":"10.1038\/s41467-020-16954-7"},{"key":"7929_CR18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.cell.2020.03.035","volume":"181","author":"Y. -Z. Zhang","year":"2020","unstructured":"Zhang, Y. -Z. & Holmes, E. C. A genomic perspective on the origin and emergence of SARS-CoV-2. Cell 181, 223\u2013227 (2020).","journal-title":"Cell"},{"key":"7929_CR19","doi-asserted-by":"publisher","first-page":"6746","DOI":"10.1039\/D1CP00266J","volume":"23","author":"E. Awoonor-Williams","year":"2021","unstructured":"Awoonor-Williams, E. & Abu-Saleh, A. A. Covalent and non-covalent binding free energy calculations for peptidomimetic inhibitors of SARS-CoV-2 main protease. Phys. Chem. Chem. Phys. 23, 6746\u20136757 (2021).","journal-title":"Phys. Chem. Chem. Phys."},{"key":"7929_CR20","unstructured":"Liu, Y., Ming, W., Li, C.-Z., Zhu, Y.-Y. & Gu, S.-X. Advances in peptidomimetic inhibitors of coronavirus main protease. Acta Pharm. Sin. 57, 1977\u20131990 (2022)."},{"key":"7929_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2022.105450","volume":"208","author":"W. Shang","year":"2022","unstructured":"Shang, W. et al. In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2. Antivir. Res. 208, 105450 (2022).","journal-title":"Antivir. Res."},{"key":"7929_CR22","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1126\/science.abb4489","volume":"368","author":"W. Dai","year":"2020","unstructured":"Dai, W. et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 368, 1331\u20131335 (2020).","journal-title":"Science"},{"key":"7929_CR23","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1021\/acscentsci.3c00538","volume":"9","author":"Y. Hu","year":"2023","unstructured":"Hu, Y. et al. Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir. ACS Cent. Sci. 9, 1658\u20131669 (2023).","journal-title":"ACS Cent. Sci."},{"key":"7929_CR24","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.3390\/ijms23073507","volume":"23","author":"J. A. M\u00f3ty\u00e1n","year":"2022","unstructured":"M\u00f3ty\u00e1n, J. A., Mahdi, M., Hoffka, G. & T\u0151zs\u00e9r, J. Potential resistance of SARS-CoV-2 main protease (Mpro) against protease inhibitors: lessons learned from HIV-1 protease. Int. J. Mol. Sci. 23, 3507 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"7929_CR25","doi-asserted-by":"publisher","first-page":"e1011592","DOI":"10.1371\/journal.ppat.1011592","volume":"19","author":"J. Ou","year":"2023","unstructured":"Ou, J. et al. A yeast-based system to study SARS-CoV-2 Mpro structure and to identify nirmatrelvir resistant mutations. PLoS Pathog. 19, e1011592 (2023).","journal-title":"PLoS Pathog."},{"key":"7929_CR26","doi-asserted-by":"crossref","unstructured":"Tran, N. et al. The H163A mutation unravels an oxidized conformation of the SARS-CoV-2 main protease. Nat. Commun. 14, 5625 (2023).","DOI":"10.1038\/s41467-023-40023-4"},{"key":"7929_CR27","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/s41586-023-06609-0","volume":"622","author":"Y. Duan","year":"2023","unstructured":"Duan, Y. et al. Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir. Nature 622, 376\u2013382 (2023).","journal-title":"Nature"},{"key":"7929_CR28","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","volume":"613","author":"S. Iketani","year":"2023","unstructured":"Iketani, S. et al. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature 613, 558\u2013564 (2023).","journal-title":"Nature"},{"key":"7929_CR29","doi-asserted-by":"crossref","unstructured":"Zhu, Y. et al. In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance. Sci. Adv. 10, eadl4013 (2024).","DOI":"10.1126\/sciadv.adl4013"},{"key":"7929_CR30","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41392-023-01392-w","volume":"8","author":"C. Huang","year":"2023","unstructured":"Huang, C. et al. A new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variants. Signal Transduct. Target. Ther. 8, 128 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"7929_CR31","doi-asserted-by":"publisher","first-page":"9837","DOI":"10.3390\/ijms22189837","volume":"22","author":"T. Nakayoshi","year":"2021","unstructured":"Nakayoshi, T., Kato, K., Kurimoto, E. & Oda, A. Virtual alanine scan of the main protease active site in severe acute respiratory syndrome coronavirus 2. Int. J. Mol. Sci. 22, 9837 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"7929_CR32","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.scib.2020.10.018","volume":"66","author":"J. Li","year":"2021","unstructured":"Li, J. et al. Crystal structure of SARS-CoV-2 main protease in complex with the natural product inhibitor shikonin illuminates a unique binding mode. Sci. Bull. 66, 661\u2013663 (2021).","journal-title":"Sci. Bull."},{"key":"7929_CR33","doi-asserted-by":"crossref","unstructured":"Wang, W. -w. et al. Structural Basis of Main Proteases of Coronavirus Bound to Bofutrelvir. J. Mol. Biol. 436, 168784 (2024).","DOI":"10.1016\/j.jmb.2024.168784"},{"key":"7929_CR34","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11481-020-09944-5","volume":"15","author":"J. Machhi","year":"2020","unstructured":"Machhi, J. et al. The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections. J. Neuroimmune Pharmacol. 15, 359\u2013386 (2020).","journal-title":"J. Neuroimmune Pharmacol."},{"key":"7929_CR35","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3390\/pathogens10020114","volume":"10","author":"E. Janik","year":"2021","unstructured":"Janik, E., Bartos, M., Niemcewicz, M., Gorniak, L. & Bijak, M. SARS-CoV-2: outline, prevention, and decontamination. Pathogens 10, 114 (2021).","journal-title":"Pathogens"},{"key":"7929_CR36","doi-asserted-by":"publisher","first-page":"127377","DOI":"10.1016\/j.bmcl.2020.127377","volume":"30","author":"S. Ullrich","year":"2020","unstructured":"Ullrich, S. & Nitsche, C. The SARS-CoV-2 main protease as drug target. Bioorg. Med. Chem. Lett. 30, 127377 (2020).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"7929_CR37","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.abb3405","volume":"368","author":"L. Zhang","year":"2020","unstructured":"Zhang, L. et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors. Science 368, 409\u2013412 (2020).","journal-title":"Science"},{"key":"7929_CR38","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bbrc.2022.09.010","volume":"629","author":"A. K. Padhi","year":"2022","unstructured":"Padhi, A. K. & Tripathi, T. Hotspot residues and resistance mutations in the nirmatrelvir-binding site of SARS-CoV-2 main protease: Design, identification, and correlation with globally circulating viral genomes. Biochem. Biophys. Res. Commun. 629, 54\u201360 (2022).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"7929_CR39","doi-asserted-by":"publisher","first-page":"e02815","DOI":"10.1128\/mbio.02815-22","volume":"14","author":"D. Jochmans","year":"2023","unstructured":"Jochmans, D. et al. The substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor in vitro and confer resistance to nirmatrelvir. MBio 14, e02815\u2013e02822 (2023).","journal-title":"MBio"},{"key":"7929_CR40","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add7197","volume":"8","author":"Y. Zhou","year":"2022","unstructured":"Zhou, Y. et al. Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system. Sci. Adv. 8, eadd7197 (2022).","journal-title":"Sci. Adv."},{"key":"7929_CR41","doi-asserted-by":"crossref","unstructured":"Shaqra, A. M. et al. Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance. Nat. Commun. 13, 3556 (2022).","DOI":"10.1038\/s41467-022-31210-w"},{"key":"7929_CR42","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1042\/BCJ20230027","volume":"480","author":"K. Al Adem","year":"2023","unstructured":"Al Adem, K., Ferreira, J. C., Fadl, S., Mustafa, M. & Rabeh, W. M. Key allosteric and active site residues of SARS-CoV-2 3CLpro are promising drug targets. Biochem. J. 480, 791\u2013813 (2023).","journal-title":"Biochem. J."},{"key":"7929_CR43","doi-asserted-by":"crossref","unstructured":"Weng, Y. L. et al. Molecular dynamics and in silico mutagenesis on the reversible inhibitor-bound SARS-CoV-2 main protease complexes reveal the role of lateral pocket in enhancing the ligand affinity. Sci. Rep. 11, 7429 (2021).","DOI":"10.1038\/s41598-021-86471-0"},{"key":"7929_CR44","doi-asserted-by":"crossref","unstructured":"Shitrit, A. et al. Conserved interactions required for inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Sci. Rep. 10, 20808 (2020).","DOI":"10.1038\/s41598-020-77794-5"},{"key":"7929_CR45","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s44298-024-00028-2","volume":"2","author":"L. Krismer","year":"2024","unstructured":"Krismer, L. et al. Study of key residues in MERS-CoV and SARS-CoV-2 main proteases for resistance against clinically applied inhibitors nirmatrelvir and ensitrelvir. npj Viruses 2, 23 (2024).","journal-title":"npj Viruses"},{"key":"7929_CR46","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jmb.2005.09.012","volume":"354","author":"J. Tan","year":"2005","unstructured":"Tan, J. et al. pH-dependent conformational flexibility of the SARS-CoV main proteinase (Mpro) dimer: molecular dynamics simulations and multiple X-ray structure analyses. J. Mol. Biol. 354, 25\u201340 (2005).","journal-title":"J. Mol. Biol."},{"key":"7929_CR47","doi-asserted-by":"crossref","unstructured":"Hilgenfeld, R. et al. in The Nidoviruses (eds Stanley, P. & Kathryn, V. H.) 581, 585\u2013591 (Springer US, 2006).","DOI":"10.1007\/978-0-387-33012-9_106"},{"key":"7929_CR48","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1080\/22221751.2021.1899770","volume":"10","author":"Y. Shi","year":"2021","unstructured":"Shi, Y. et al. The preclinical inhibitor GS441524 in combination with GC376 efficaciously inhibited the proliferation of SARS-CoV-2 in the mouse respiratory tract. Emerg. Microbes Infect. 10, 481\u2013492 (2021).","journal-title":"Emerg. Microbes Infect."},{"key":"7929_CR49","first-page":"e01253","volume":"96","author":"Y. Zhang","year":"2022","unstructured":"Zhang, Y. et al. Structure-based discovery and structural basis of a novel broad-spectrum natural product against the main protease of coronavirus. J. Virol. 96, e01253\u201301221 (2022).","journal-title":"J. Virol."},{"key":"7929_CR50","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","volume":"374","author":"D. R. Owen","year":"2021","unstructured":"Owen, D. R. et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science 374, 1586\u20131593 (2021).","journal-title":"Science"},{"key":"7929_CR51","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J. Hammond","year":"2022","unstructured":"Hammond, J. et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N. Engl. J. Med. 386, 1397\u20131408 (2022).","journal-title":"N. Engl. J. Med."},{"key":"7929_CR52","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s13238-021-00883-2","volume":"13","author":"Y. Zhao","year":"2022","unstructured":"Zhao, Y. et al. Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332. Protein Cell 13, 689\u2013693 (2022).","journal-title":"Protein Cell"},{"key":"7929_CR53","doi-asserted-by":"crossref","unstructured":"Liu, K. et al. BL02U1: the relocated macromolecular crystallography beamline at the Shanghai Synchrotron Radiation Facility. Nucl. Sci. Tech. 34, 193 (2023).","DOI":"10.1007\/s41365-023-01348-3"},{"key":"7929_CR54","doi-asserted-by":"crossref","unstructured":"Xu, Q. et al. The biosafety level-2 macromolecular crystallography beamline (BL10U2) at the Shanghai Synchrotron Radiation Facility. Nucl. Sci. Tech. 34, 202 (2023).","DOI":"10.1007\/s41365-023-01350-9"},{"key":"7929_CR55","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1107\/S1600576719001183","volume":"52","author":"F. Yu","year":"2019","unstructured":"Yu, F. et al. Aquarium: an automatic data-processing and experiment information management system for biological macromolecular crystallography beamlines. J. Appl. Crystallogr. 52, 472\u2013477 (2019).","journal-title":"J. Appl. Crystallogr."},{"key":"7929_CR56","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"A. J. McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658\u2013674 (2007).","journal-title":"J. Appl. Crystallogr."},{"key":"7929_CR57","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"P. D. Adams","year":"2010","unstructured":"Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. Sect. D. 66, 213\u2013221 (2010).","journal-title":"Acta Crystallogr. Sect. D."},{"key":"7929_CR58","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P. Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. Sect. D. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. Sect. D."},{"key":"7929_CR59","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1107\/S0907444909042073","volume":"66","author":"V. B. Chen","year":"2010","unstructured":"Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. Sect. D. 66, 12\u201321 (2010).","journal-title":"Acta Crystallogr. Sect. D."},{"key":"7929_CR60","unstructured":"DeLano, W. L. The PyMOL molecular graphics system. http:\/\/www.pymol.org\/ (2002)."},{"key":"7929_CR61","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/jcc.20291","volume":"26","author":"D. Van Der Spoel","year":"2005","unstructured":"Van Der Spoel, D. et al. GROMACS: fast, flexible, and free. J. Comput. Chem. 26, 1701\u20131718 (2005).","journal-title":"J. Comput. Chem."},{"key":"7929_CR62","doi-asserted-by":"crossref","unstructured":"Abraham, M. J. et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX1-2, 19\u201325 (2015).","DOI":"10.1016\/j.softx.2015.06.001"},{"key":"7929_CR63","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1002\/prot.22711","volume":"78","author":"K. Lindorff-Larsen","year":"2010","unstructured":"Lindorff-Larsen, K. et al. Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins 78, 1950\u20131958 (2010).","journal-title":"Proteins"},{"key":"7929_CR64","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1007\/s00894-010-0650-7","volume":"16","author":"G. A. \u00d6zp\u0131nar","year":"2010","unstructured":"\u00d6zp\u0131nar, G. A., Peukert, W. & Clark, T. An improved generalized AMBER force field (GAFF) for urea. J. Mol. Model. 16, 1427\u20131440 (2010).","journal-title":"J. Mol. Model."},{"key":"7929_CR65","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1021\/ct2002732","volume":"7","author":"D. Nayar","year":"2011","unstructured":"Nayar, D., Agarwal, M. & Chakravarty, C. Comparison of tetrahedral order, liquid state anomalies, and hydration behavior of mTIP3P and TIP4P water models. J. Chem. Theory Comput. 7, 3354\u20133367 (2011).","journal-title":"J. Chem. Theory Comput."},{"key":"7929_CR66","doi-asserted-by":"publisher","first-page":"025304","DOI":"10.1103\/PhysRevE.104.025304","volume":"104","author":"S. M. Donnelly","year":"2021","unstructured":"Donnelly, S. M., Lopez, N. A. & Dodin, I.Y. Steepest-descent algorithm for simulating plasma-wave caustics via metaplectic geometrical optics. Phys. Rev. E 104, 025304 (2021).","journal-title":"Phys. Rev. E"},{"key":"7929_CR67","doi-asserted-by":"publisher","first-page":"8577","DOI":"10.1063\/1.470117","volume":"103","author":"U. Essmann","year":"1995","unstructured":"Essmann, U. et al. A smooth particle mesh Ewald method.  J. Chem. Phys. 103, 8577\u20138593 (1995).","journal-title":"J. Chem. Phys."},{"key":"7929_CR68","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H","volume":"18","author":"B. Hess","year":"1997","unstructured":"Hess, B., Bekker, H., Berendsen, H. J. C. & Fraaije, J. G. E. M. LINCS: A linear constraint solver for molecular simulations. J. Comput. Chem. 18, 1463\u20131472 (1997).","journal-title":"J. Comput. Chem."},{"key":"7929_CR69","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1063\/1.448118","volume":"81","author":"H. J. C. Berendsen","year":"1984","unstructured":"Berendsen, H. J. C., Postma, J. P. M., Gunsteren, W. F. V., Dinola, A. & Haak, J. R. Molecular dynamics with coupling to an external bath. J. Chem. Phys. 81, 3684\u20133690 (1984).","journal-title":"J. Chem. Phys."},{"key":"7929_CR70","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3390\/e16010138","volume":"16","author":"N. Bou-Rabee","year":"2014","unstructured":"Bou-Rabee, N. Time Integrators for Molecular Dynamics. Entropy 16, 138\u2013162 (2014).","journal-title":"Entropy"},{"key":"7929_CR71","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","volume":"10","author":"S. Genheden","year":"2015","unstructured":"Genheden, S. & Ryde, U. The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities. Expert Opin. drug Discov. 10, 449\u2013461 (2015).","journal-title":"Expert Opin. drug Discov."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-07929-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-07929-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-07929-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T01:04:36Z","timestamp":1743296676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-07929-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7929"],"URL":"https:\/\/doi.org\/10.1038\/s42003-025-07929-9","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"6 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"493"}}